Presented by Dmitry Gabrilovich, executive director and chief scientist in cancer immunology at AstraZeneca, whose research focuses on investigation of the mechanisms of the activity of immuno/oncology drugs, discovery of mechanisms regulating function of myeloid cells in cancer, and the development of new targeting opportunities. He is the highly cited researcher in immune/oncology and was awarded the title of research professor by the American Cancer Society.